Elucida Oncology is a Clinical stage biotechnology company focused on development of targeted drug conjugates utilizing it's proprietary C'Dot platform. This platform enables the development of targeted conjugates that outperform antibody-drug-conjugates through enhanced targeting capabilities, greater payload delivery, solid tumor penetration and shorter systemic exposure. The platform is amenable to nearly all small molecule drugs and a wide variety of cancer targets, enabling development of a broad portfolio of products and significant strategic partnership opportunity.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
ELU001 (Folate Receptor Alpha - CDC)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
